Free tool
FAERS Monitor: Atacand
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020838 or its brand name (Atacand, Candesartan Cilexetil). Reports on generic versions are filed under their own applications.
Reports
26,474
Serious
23,278
88% of reports
Hospitalization
12,870
Death reported
2,476
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,752
- fatigue1,751
- nausea1,666
- headache1,637
- drug ineffective1,623
- dizziness1,519
- diarrhoea1,389
- malaise1,380
- off label use1,330
- fall1,296
- pain1,249
- vomiting1,164
- hypertension1,160
- blood pressure increased1,156
- asthenia1,096
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 461 |
| 2005 | 543 |
| 2006 | 609 |
| 2007 | 853 |
| 2008 | 909 |
| 2009 | 1,077 |
| 2010 | 1,382 |
| 2011 | 2,050 |
| 2012 | 2,398 |
| 2013 | 1,086 |
| 2014 | 988 |
| 2015 | 977 |
| 2016 | 843 |
| 2017 | 815 |
| 2018 | 1,332 |
| 2019 | 1,424 |
| 2020 | 1,455 |
| 2021 | 1,261 |
| 2022 | 1,313 |
| 2023 | 1,225 |
| 2024 | 1,243 |
| 2025 | 1,195 |
| 2026 | 1,034 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,685 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 1,156 | 6.0 | 5.7 | 4,861 |
| hypertensionSignal | 1,160 | 4.4 | 4.1 | 3,025 |
| fallSignal | 1,296 | 3.1 | 2.9 | 1,866 |
| malaiseSignal | 1,380 | 2.5 | 2.4 | 1,268 |
| dyspnoeaSignal | 1,752 | 2.5 | 2.4 | 1,559 |
| dizzinessSignal | 1,519 | 2.4 | 2.3 | 1,296 |
| astheniaSignal | 1,096 | 2.3 | 2.2 | 834 |
| headacheSignal | 1,637 | 2.1 | 2.0 | 939 |
| vomiting | 1,164 | 2.0 | 1.9 | 566 |
| fatigue | 1,751 | 1.8 | 1.7 | 630 |
| diarrhoea | 1,389 | 1.7 | 1.6 | 422 |
| nausea | 1,666 | 1.7 | 1.6 | 468 |
| pain | 1,249 | 1.6 | 1.5 | 301 |
| off label use | 1,330 | 1.2 | 1.1 | 49 |
| drug ineffective | 1,623 | 1.0 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.